Notice: This company has been marked as potentially delisted and may not be actively trading. Alpine Immune Sciences (ALPN) Stock Forecast & Price Target Add Compare Share Share Analyst Forecasts Stock AnalysisAnalyst ForecastsCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipShort InterestTrends Get the Latest News and Ratings for ALPN and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Alpine Immune Sciences and its competitors. Enter your email to sign up for newsletter Sign Up ALPN Analyst Ratings Over TimeTypeCurrent Forecast10/6/23 to 10/5/241 Month Ago9/6/23 to 9/5/243 Months Ago7/8/23 to 7/7/241 Year Ago10/6/22 to 10/6/23Strong Buy0 Strong Buy rating(s)0 Strong Buy rating(s)0 Strong Buy rating(s)0 Strong Buy rating(s)Buy3 Buy rating(s)3 Buy rating(s)3 Buy rating(s)6 Buy rating(s)Hold8 Hold rating(s)8 Hold rating(s)8 Hold rating(s)0 Hold rating(s)Sell0 Sell rating(s)0 Sell rating(s)0 Sell rating(s)0 Sell rating(s)Consensus Price Target$52.33$52.33$52.33$18.17Forecasted Upside-19.45% Downside-19.45% Downside-19.45% Downside49.03% UpsideConsensus RatingHoldHoldHoldBuy ⭕ [URGENT] Buy Alert just triggered (Ad)My absolute favorite stock just hit a critical "buy now" trigger price.Click here for the ticker >>> ALPN Analyst Recommendations By MonthAnalyst Ratings Chart DescriptionThe chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.Skip Chart & View Analyst Rating History ALPN Price Targets by MonthAverage Share Price and Price Target by Month Chart DescriptionThe chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table Alpine Immune Sciences Stock vs. The CompetitionTypeAlpine Immune SciencesMedical CompaniesS&P 500Consensus Rating Score 2.27 2.79 2.50Consensus RatingHoldModerate BuyModerate BuyPredicted Upside-19.45% Downside10,587.31% Upside7.01% UpsideNews Sentiment RatingNeutral NewsSee Recent ALPN NewsPositive NewsPositive News Recent Analyst Forecasts and Stock Ratings All Ratings Strong Buy Buy Hold Sell Rating Show All Upside > 100% Upside 50% - 100% Upside 20% - 50% Upside 10% - 20% Upside 0% - 10% Downside 0% - 10% Downside 10% - 20% Downside 20% - 50% Downside 50% - 100% Downside > 100% Upside/Downside All Actions Upgrades Downgrades Initiates Coverage Raises Target Lowers Target Reiterates Rating Action Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 3 Years 5 Years Time Frame Start Date End Date Most Recent from Each Brokerage All Show Export to Excel DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails5/16/2024Wedbush3 of 5 starsR. DriscollSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$65.00+0.05%4/16/2024TD Cowen4 of 5 stars Reiterated RatingBuy ➝ Hold4/12/2024Leerink Partners1 of 5 stars DowngradeOutperform ➝ Market Perform$42.00 ➝ $65.00+0.87%4/11/2024Leerink PartnrsSubscribe to MarketBeat All Access for the recommendation accuracy ratingT. SmithSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Market Perform4/11/2024HC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingJ. PantginisSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral4/11/2024Morgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy rating Reiterated RatingOverweight ➝ Equal Weight$47.00 ➝ $65.00+38.18% Get the Latest News and Ratings for ALPN and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Alpine Immune Sciences and its competitors with MarketBeat's FREE daily newsletter. 4/11/2024Royal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy rating Reiterated RatingOutperform ➝ Sector Perform$41.00 ➝ $65.00+38.18%4/11/2024Wolfe ResearchSubscribe to MarketBeat All Access for the recommendation accuracy rating Reiterated RatingOutperform ➝ Peer Perform4/9/2024GuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy rating Initiated CoverageBuy$55.00+42.75%3/19/2024OppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy rating Reiterated RatingOutperform ➝ Outperform$33.00 ➝ $44.00+24.05%10/17/2023Berenberg BankSubscribe to MarketBeat All Access for the recommendation accuracy rating Initiated CoverageBuy$18.00+80.00%Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 08:22 AM ET. ALPN Forecast - Frequently Asked Questions What is Alpine Immune Sciences' forecast for 2024? According to the research reports of 11 Wall Street equities research analysts, the average twelve-month stock price forecast for Alpine Immune Sciences is $52.33, with a high forecast of $65.00 and a low forecast of $18.00. Should I buy or sell Alpine Immune Sciences stock right now? 11 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Alpine Immune Sciences in the last year. There are currently 8 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" ALPN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ALPN, but not buy additional shares or sell existing shares. Does Alpine Immune Sciences's stock price have much downside? According to analysts, Alpine Immune Sciences's stock has a predicted downside of -19.45% based on their 12-month stock forecasts. Do Wall Street analysts like Alpine Immune Sciences more than its competitors? Analysts like Alpine Immune Sciences less than other "medical" companies. The consensus rating for Alpine Immune Sciences is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how ALPN compares to other companies. Stock Forecasts and Research Tools Related Companies: XNCR Stock Forecast ZYME Stock Forecast MGNX Stock Forecast ASMB Stock Forecast SMMT Stock Forecast RPRX Stock Forecast GMAB Stock Forecast UTHR Stock Forecast VTRS Stock Forecast BMRN Stock Forecast Today's Ratings: U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top Rated Stocks: Top Rated Stocks Top Rated Dividend Stocks Top Rated Small-Cap Stocks Top Rated Tech Stocks Most Upgraded Stocks Most Downgraded Stocks Lowest Rated Stocks More Ratings Tools: Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Who are Nvidia’s New Silent Partners? (Ad)Nvidia knows it can’t stand still as AI continues to grow at an exponential rate. That’s why CEO Jensen Huang consistently has his company ahead of the curve when it comes to artificial intelligence. Nvidia’s added $2 trillion in market cap in 2024.I call these Nvidia’s “Silent Partners.” This page (NASDAQ:ALPN) was last updated on 10/5/2024 by MarketBeat.com Staff From Our PartnersCNBC’s ‘Prophet’ issues urgent Fed warning"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all...Stansberry Research | SponsoredHow a $200,000 Mistake Unlocked a $118 Billion Gold TreasureThe window of opportunity on this gold stock is closing fast. Once word gets out, it may be too late.Monument Traders Alliance | Sponsored“A very dark day is coming to America”Wall Street Legend on Economy: "If you knew what I know, you'd be terrified too." Something huge is headed ...InvestorPlace | SponsoredGolden Equation: Volatility = OpportunityWhen the market swings wildly, most investors panic… But it doesn't have to be this way. You see, when t...Prosper Trading Academy | SponsoredAI expert reveals new Nvidia predictionEveryone’s talking about AI right now, but I’ve been talking about it for years. And now I’ve just released...Brownstone Research | SponsoredNext opportunity for crypto millionsAll the Pieces Falling into Place for Crypto… Unlock the Potential of the 2024 Crypto Bull Run!Crypto 101 Media | SponsoredRetire off just one stock ticker?ONE AI Stock is All You Need... There are over 6,000 stocks listed in the market right now. They will NOT m...Behind the Markets | SponsoredWho are Nvidia’s New Silent Partners?Nvidia recently became just the third $2 trillion company. But Nvidia can’t do everything by itself.Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alpine Immune Sciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Alpine Immune Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
